PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma.
cholangiocarcinoma
immune cells
immune checkpoint
liver cancer
nerve fiber density
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Apr 2022
27 Apr 2022
Historique:
received:
30
03
2022
revised:
15
04
2022
accepted:
19
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
Perihilar cholangiocarcinoma (pCCA) is a hepatobiliary malignancy, with a dismal prognosis. Nerve fiber density (NFD)-a novel prognostic biomarker-describes the density of small nerve fibers without cancer invasion and is categorized into high numbers and low numbers of small nerve fibers (high vs low NFD). NFD is different than perineural invasion (PNI), defined as nerve fiber trunks invaded by cancer cells. Here, we aim to explore differences in immune cell populations and survival between high and low NFD patients. We applied multiplex immunofluorescence (mIF) on 47 pCCA patients and investigated immune cell composition in the tumor microenvironment (TME) of high and low NFD. Group comparison and oncological outcome analysis was performed. CD8+PD-1 expression was higher in the high NFD than in the low NFD group (12.24 × 10 PD-1+ T-cells correlate with high NFD as a prognostic biomarker and predict good survival; the biological pathway needs to be investigated.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Perihilar cholangiocarcinoma (pCCA) is a hepatobiliary malignancy, with a dismal prognosis. Nerve fiber density (NFD)-a novel prognostic biomarker-describes the density of small nerve fibers without cancer invasion and is categorized into high numbers and low numbers of small nerve fibers (high vs low NFD). NFD is different than perineural invasion (PNI), defined as nerve fiber trunks invaded by cancer cells. Here, we aim to explore differences in immune cell populations and survival between high and low NFD patients.
APPROACH AND RESULTS
RESULTS
We applied multiplex immunofluorescence (mIF) on 47 pCCA patients and investigated immune cell composition in the tumor microenvironment (TME) of high and low NFD. Group comparison and oncological outcome analysis was performed. CD8+PD-1 expression was higher in the high NFD than in the low NFD group (12.24 × 10
CONCLUSIONS
CONCLUSIONS
PD-1+ T-cells correlate with high NFD as a prognostic biomarker and predict good survival; the biological pathway needs to be investigated.
Identifiants
pubmed: 35565318
pii: cancers14092190
doi: 10.3390/cancers14092190
pmc: PMC9103905
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : China Scholarship Council
ID : 201806210074
Références
Hepatology. 2022 Feb;75(2):297-308
pubmed: 34510503
J Immunother Cancer. 2016 Jan 19;4:3
pubmed: 26788324
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
BMC Cancer. 2020 Mar 30;20(1):270
pubmed: 32228636
Hernia. 2020 Dec;24(6):1175-1189
pubmed: 33030647
Clin Cancer Res. 2022 Feb 1;28(3):540-551
pubmed: 34785581
Hepatology. 2014 Jun;59(6):2397-402
pubmed: 24123296
Cancer Manag Res. 2018 Oct 02;10:4113-4123
pubmed: 30323667
Oncoimmunology. 2017 Jan 3;6(2):e1273309
pubmed: 28344887
Histopathology. 2017 Sep;71(3):383-392
pubmed: 28419539
Oncotarget. 2017 Apr 11;8(15):24644-24651
pubmed: 28445951
Gastroenterology. 2012 Apr;142(4):1021-1031.e15
pubmed: 22178589
Front Oncol. 2019 Sep 18;9:897
pubmed: 31620360
Liver Int. 2019 May;39 Suppl 1:108-122
pubmed: 30843325
Cancers (Basel). 2022 Mar 29;14(7):
pubmed: 35406520
Br J Cancer. 2018 Jan;118(2):171-180
pubmed: 29123259
Int J Cancer. 2020 Oct 15;147(8):2190-2198
pubmed: 32359091
Nat Commun. 2014 Dec 15;5:5696
pubmed: 25526346
Expert Opin Investig Drugs. 2021 Oct;30(10):1007-1015
pubmed: 34459336
World J Surg Oncol. 2020 Nov 23;18(1):303
pubmed: 33228682
Ann Surg Oncol. 2020 Feb;27(2):599-607
pubmed: 31407173
Br J Cancer. 2020 Sep;123(7):1047-1059
pubmed: 32694694
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):527-536
pubmed: 33215952
Expert Opin Investig Drugs. 2021 Apr;30(4):351-363
pubmed: 33382361
Lancet Oncol. 2019 May;20(5):663-673
pubmed: 30922733
Gastroenterology. 2013 Apr;144(4):829-40
pubmed: 23295441
Liver Cancer. 2021 Sep 21;10(6):545-560
pubmed: 34950178
Liver Cancer. 2021 Jun;10(3):260-274
pubmed: 34239812
J Hepatol. 2020 Dec;73(6):1460-1469
pubmed: 32710922
Cancers (Basel). 2021 Jul 21;13(15):
pubmed: 34359564
Expert Opin Investig Drugs. 2021 Apr;30(4):343-350
pubmed: 33645367
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Expert Opin Investig Drugs. 2021 Apr;30(4):325-332
pubmed: 33307866
Cancer Cell. 2017 Jul 10;32(1):57-70.e3
pubmed: 28648284
Cancer Discov. 2017 Oct;7(10):1116-1135
pubmed: 28667006
Theranostics. 2019 Jul 9;9(16):4678-4687
pubmed: 31367249
Cancer Cell. 2021 Jun 14;39(6):866-882.e11
pubmed: 33930309
Ann Surg Oncol. 2016 Aug;23(8):2610-7
pubmed: 27012989
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
J Clin Med. 2021 Jan 30;10(3):
pubmed: 33573277
Hepatology. 2020 Sep;72(3):965-981
pubmed: 31875970
Eur J Surg Oncol. 2022 Mar;48(3):604-614
pubmed: 34565633
J Hepatol. 2019 Jul;71(1):104-114
pubmed: 30910538
Br J Cancer. 2013 Nov 12;109(10):2665-74
pubmed: 24136146
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):611-621
pubmed: 31109808